Progress towards an HIV cure: Update from the 2014 international AIDS society symposium

AIDS Research and Human Retroviruses

Volumn 31, Issue 1, 2015, Pages 36-44

  Anderson, Jenny L ^a   Fromentin, Rémi ^b   Corbelli, Giulio Maria ^c   Østergaard, Lars ^d   Ross, Anna Laura ^e,f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Vaccine and Gene Therapy Institute of Florida   (United States)

^c EUROPEAN AIDS TREATMENT GROUP   (Belgium)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e ANRS   (France)

^f UNAIDS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BENZOTRIAZOLE DERIVATIVE; BISPECIFIC ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUTRALIZING ANTIBODY; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

AUSTRALIA; CONFERENCE PAPER; DISEASE CARRIER; EFFECTOR CELL; EX VIVO STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; LATENT PERIOD; MEDICAL RESEARCH; PRIORITY JOURNAL; TREATMENT INDICATION; VACCINATION; VIRUS REACTIVATION; ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG EFFECTS; ENZYME ACTIVATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; METABOLISM; PROCEDURES; TREATMENT OUTCOME; VIROLOGY; VIRUS LATENCY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMEDICAL RESEARCH; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME ACTIVATION; HUMANS; NF-KAPPA B; POSITIVE TRANSCRIPTIONAL ELONGATION FACTOR B; TREATMENT OUTCOME; VIRUS LATENCY;

EID: 84928955777     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0236     Document Type: Conference Paper

References (56)

1. Henrich TJ, Hanhauser E, Marty FM, et al.: Antiretroviralfree HIV-1 remission and viral rebound after allogeneic stem cell transplantation: Report of 2 cases. Ann Intern Med 2014;161(5):319-327
2. Henrich TJ, Hu Z, Li JZ, et al.: Long-term reduction in peripheral blood HIV type 1 reservoirs following reducedintensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013;207(11):1694-1702
3. Fennessey CR and Keele B: Ultra-deep barcoded SIVmac259 to identify and quantify viral reservoirs and recrudescent viremia. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
4. Hecht FM and Palmer S: Genetically characterizing the role of cell proliferation in maintaining persistent HIV during effective HIV therapy. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
5. Fromentin R, Bakeman W, Lawani MB, et al.: The immune checkpoint blockers PD-1, LAG-3 and TIGIT are biomarkers of HIV infected cells during ART and identify distinct cellular reservoirs. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
6. Evans VA, Kumar N, Filali A, et al.: Myeloid dendritic cells induce HIV-1 latency in non-proliferating CD4 +T cells. PLoS Pathog 2013;9(12):e1003799
7. Evans VA, van der Sluis RM, Kumar NA, et al.: Following in vitro culture with myeloid dendritic cells, negative regulators of T-cell activation are expressed preferentially on latently infected CD4 + T-cells. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
8. International ASSWGoHIVC, Deeks SG, Autran B, et al.: Towards an HIV cure: A global scientific strategy. Nat Rev Immunol 2012;12(8):607-614
9. Ho YC, Shan L, Hosmane NN, et al.: Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013;155(3):540-551
10. Procopio FA, Fromentin R, Kulpa D, et al.: A novel assay that precisely measures the size of the latent HIV reservoir reveal that ART-naive individuals harbour a large pool of latently infected CD4 + T-cells. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
11. Whitney JB, Hill AL, Sanisetty S, et al.: Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 2014;512(7512):74-77
12. Rouzioux C: Impact of antiretroviral treatment on HIV reservoirs. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
13. Deeks SG: HIV: Shock and kill. Nature 2012;487(7408):439-440
14. Wightman F, Ellenberg P, Churchill M, and Lewin SR: HDAC inhibitors in HIV. Immunol Cell Biol 2012;90(1):47-54
15. Spina CA, Anderson J, Archin NM, et al.: An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4 + T cells from aviremic patients. PLoS Pathog 2013;9(12):e1003834
16. Tolstrup M, Vigano S, Olesen R, et al.: Immunological correlates of HIV-1 DNA decline during latency reversal with panobinostat in patients on suppressive cART. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
17. Rasmussen TA, Tolstrup M, Brinkmann CR, et al.: Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: A phase 1/2, single group, clinical trial. Lancet HIV 2014;1(1):e13-e21
18. Søgaard OS, Graversen ME, Leth S, et al.: The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
19. Wei DG, Chiang V, Fyne E, et al.: Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 2014;10(4):e1004071
20. Wightman F, Elliot JH, Solomon AE, et al.: Multidose vorinostat in HIV-infected individuals on effective ART leads to an increase in regulatory T-cells but no change in inducible virus or HIV-specific T-cells. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
21. Darcis G, Kula A, Bouchat K, et al.: Synergistic activation of HIV-1 expression by compounds releasing active positive transcription elongation factor b (P-TEFb) and by inducers of the NF-kB signaling pathway. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
22. Abreu CM, Price SL, Shirk EN, et al.: Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: Inhibition of de novo infection and activation of viral LTR. PLoS One 2014;9(5):e97257
23. Jiang G, Mendes EA, Kaiser P, et al.: Reactivation of HIV latency by a newly modified ingenol derivative via protein kinase Cdelta-NF-kappaB signaling. AIDS 2014;28(11):1555-1566
24. Boehm D, Calvanese V, Dar RD, et al.: BET bromodomaintargeting compounds reactivate HIV from latency via a Tatindependent mechanism. Cell Cycle 2013;12(3):452-462
25. Banerjee C, Archin N, Michaels D, et al.: BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 2012;92(6):1147-1154
26. Chomont N, El-Far M, Ancuta P, et al.: HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009;15(8):893-900
27. Bosque A, Novis C, Martins L, et al.: A new family of compounds that reactivate latent HIV in central memory T cells. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
28. Selliah N, Zhang M, DeSimone D, et al.: The gammaccytokine regulated transcription factor, STAT5, increases HIV-1 production in primary CD4 T cells. Virology 2006;344(2):283-291
29. Carta A, Palomba M, Boatto G, et al.: Synthesis and antiproliferative activity of 3-aryl-2-[1H(2H)-benzotriazol-1(2)-yl]acrylonitriles variously substituted: Part 4. Farmaco 2004;59(8):637-644
30. Archin NM, Liberty AL, Kashuba AD, et al.: Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012;487(7408):482-485
31. Spivak AM, Andrade A, Eisele E, et al.: A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis 2014;58(6):883-890
32. Elliott JAS: the safety and effect of multiple doses of vorinostat on HIV transcription in HIV + patients receiving cART. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, Georgia, 2013
33. Archin NM, Bateson R, Tripathy MK, et al.: HIV-1 expression within resting CD4 + T cells after multiple doses of vorinostat. J Infect Dis 2014;210(5):728-735
34. Rasmussen T: Panobinostat induces HIV transcription and plasma viremia in HIV patients on suppressive cART. Conference on Retroviruses and Opportunistic Infections, 2014
35. Zolla-Pazner S: A critical question for HIV vaccine development: Which antibodies to induce? Science 2014;345(6193): 167-168
36. Walker LM, Huber M, Doores KJ, et al.: Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011;477(7365):466-470
37. Barouch DH: Therapeutic efficacy of neutralizing antibodies for HIV. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
38. Wu X, Yang ZY, Li Y, et al.: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010;329(5993):856-861
39. Zhou T, Georgiev I, Wu X, et al.: Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010;329(5993):811-817
40. Pegu A, Yang ZY, Boyington JC, et al.: Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med 2014;6(243):243ra288
41. Su B, Lederle A, Schmidt S, et al.: Potent and broadly anti-HIV-1 neutralizing antibody VRC01 inhibits HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
42. Barouch DH and Deeks SG: Immunologic strategies for HIV-1 remission and eradication. Science 2014;345(6193):169-174
43. Petrovas C, Ferrando-Martinez S, Pegu A, et al.: A population of CD8 T cells is located in the germinal centers that is functionally capable of mediating bi-specific antibody mediated killing of HIV-infected T-cells. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
44. Mylvaganam G, Velu V, and Amara RR: Co-localization of follicular SIV-specific CD8 T-cells with Tfh in the germinal centers of chronically SIV infected Rhesus macaques is associated with enhanced viral control. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
45. Margolis D, Garrido C, Sung JM, et al.: Induction and clearance of latent HIV infection: Modeling viral clearance by immune effectors using cells from ART-treated patients. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
46. Leen AM, Myers GD, Sili U, et al.: Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006;12(10):1160-1166
47. Bollard CM, Gottschalk S, Leen AM, et al.: Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007;110(8):2838-2845
48. Marras F, Bozzano F, Ascierto ML, and De Maria A: Baseline and dynamic expression of activating NK cell receptors in the control of chronic viral infections: The paradigm of HIV-1 and HCV. Front Immunol. 2014;5:305
49. Hansen SG, Piatak M Jr, Ventura AB, et al.: Immune clearance of highly pathogenic SIV infection. Nature 2013;502(7469):100-104
50. Lifson J: The role of therapeutic vaccination in HIV cure strategies. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
51. Fauci AS: Critical challenges in HIV discovery: Cure and vaccine. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
52. Ott M: Epigenetic regulation of HIV latency. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014
53. TAG: Research Toward a Cure Trials. www.treatmentaction group.org/cure/trials, 2014
54. Persaud D, Gay H, Ziemniak C, et al.: Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013;369(19):1828-1835
55. Saez-Cirion A, Bacchus C, Hocqueloux L, et al.: Posttreatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy: ANRS VISCONTI Study. PLoS Pathog 2013;9(3):e1003211
56. Fauci AS, Marston HD, and Folkers GK: An HIV cure: Feasibility, discovery, and implementation. JAMA 2014; 312(4):335-336